Loading
Cholangiocarcinoma and Gallbladder Cancer Studies · Journal article
Scientific Reports · August 11, 2026
Encouraging direction, but not yet definitive.
This retrospective analysis of 161 patients with unresectable pancreatic cancer treated with nanoliposomal irinotecan/fluorouracil/folinic acid found no statistically significant difference in overall survival between standard and reduced starting doses, or between relative dose intensity ≥80% and <80%. The data suggest individualized dose modification may be tolerable without compromising efficacy, but the observational design and lack of prospective validation limit the strength of evidence for changing practice.
Retrospective cohort study. 161 patients with unresectable pancreatic cancer treated with NFF (nanoliposomal irinotecan, fluorouracil, folinic acid) as second-line therapy after gemcitabine-based treatment; median age 67 years; 55% male. Intervention: Nanoliposomal irinotecan with fluorouracil and folinic acid (NFF) at standard starting dose with relative dose intensity ≥80%. Compared with: Reduced starting dose and/or relative dose intensity <80%. n = 161. 20 Japanese institutions.
OS 8.1 vs. 8.8 months for standard vs. reduced dose (p=0.47; HR 1.15) OS 7.5 vs. 9.2 months for RDI ≥80% vs. <80% (p=0.39; HR 0.85) PFS 3.4 vs. 3.2 months for standard vs. reduced dose (p=0.43)
Standard dose associated with more anemia, thrombocytopenia, and vomiting; RDI <80% with more severe non-hematologic toxicity
These findings suggest that clinicians may consider individualized dose modifications in patients receiving NFF for advanced pancreatic cancer without expected loss of survival benefit, particularly to mitigate toxicity. However, the retrospective nature and lack of randomization mean this should not yet drive routine practice changes; prospective validation is needed.
Retrospective observational study of 161 patients suggesting dose modifications do not compromise survival in second-line pancreatic cancer, but lacks randomization and prospective design to establish definitive practice guidance.
As stated by the source record.
Quoted from the source exactly as published.
These findings suggest that clinicians may consider individualized dose modifications in patients receiving NFF for advanced pancreatic cancer without expected loss of survival benefit, particularly to mitigate toxicity. However, the retrospective nature and lack of randomization mean this should not yet drive routine practice changes; prospective validation is needed.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Abstract While nanoliposomal irinotecan with fluorouracil and folinic acid (NFF) is a standard second-line regimen for unresectable pancreatic cancer (uPC) after gemcitabine-based therapy, the effects of initial dosing and relative dose intensity (RDI) in routine practice are unclear. We retrospectively analyzed 161 patients (median age 67 years; 55% male) with uPC treated with NFF at 20 Japanese institutions (June 2020–May 2021), comparing standard vs. reduced starting dose and RDI ≥80% vs. <80%. Overall survival (OS) was 8.1 vs. 8.8 months for standard vs. reduced dose ( p = 0.47; hazard ratio [HR], 1.15) and 7.5 vs. 9.2 months for RDI ≥80% vs. <80% ( p = 0.39; HR, 0.85). Progression-free survival (PFS) was 3.4 vs. 3.2 months ( p = 0.43) and 2.8 vs. 4.4 months ( p = 0.13), respectively, with similar response and disease control rates. Anemia, thrombocytopenia, and vomiting occurred more frequently in patients administered the standard starting dose, whereas severe non-hematologic adverse events were more frequently observed for RDI <80%. Reduced starting dose and RDI <80% were not associated with inferior survival, suggesting that individualized dose modification may be feasible. Future prospective studies are warranted to refine NFF dosing strategies.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.